Back to top
more

Adagene (ADAG)

(Delayed Data from NSDQ)

$2.47 USD

2.47
2,791

+0.17 (7.39%)

Updated Aug 8, 2024 02:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for ADAG

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Adagene Inc Sponsored ADR falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 110 144 174 75 101
Receivables 0 1 8 0 2
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 3 5 4 4 1
Total Current Assets 113 149 186 79 104
Net Property & Equipment 2 3 3 2 2
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 0 0 0 3 0
Total Assets 116 152 190 84 106
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 4 11 3 4 1
Accounts Payable 3 4 3 2 1
Current Portion Long-Term Debt 4 3 1 1 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 3 3 4 6 3
Income Taxes Payable 0 0 2 0 0
Other Current Liabilities 17 34 16 3 3
Total Current Liabilities 31 55 30 16 7
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 14 14 3 3 2
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 0 0 0 0 0
Minority Interest (Liabilities) 0 0 0 154 154
Total Liabilities 45 69 33 174 163
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 350 343 336 24 7
Retained Earnings -278 -259 -179 -106 -63
Other Equity -2 -1 0 -8 -1
Treasury Stock 0 0 1 0 0
Total Shareholder's Equity 71 83 157 -89 -57
Total Liabilities & Shareholder's Equity 116 152 190 84 106
Total Common Equity 71 83 157 -89 -57
Shares Outstanding 43.80 43.40 43.60 NA NA
Book Value Per Share 1.61 1.91 3.59 0.00 0.00

Fiscal Year End for Adagene Inc Sponsored ADR falls in the month of December.

All items in Millions except Per Share data.

6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Assets          
Cash & Equivalents -99,903 -99,999 110 -99,999 -99,870
Receivables 0 NA 0 NA 0
Notes Receivable NA NA 0 NA NA
Inventories NA NA 0 NA NA
Other Current Assets 3 NA 3 NA 4
Total Current Assets 99 NA 113 NA 133
Net Property & Equipment 1 NA 2 NA 2
Investments & Advances NA NA 0 NA NA
Other Non-Current Assets NA NA 0 NA NA
Deferred Charges NA NA 0 NA NA
Intangibles NA NA 0 NA NA
Deposits & Other Assets 0 NA 0 NA 0
Total Assets 101 NA 116 NA 135
Liabilities & Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Notes Payable 4 NA 4 NA 9
Accounts Payable 3 NA 3 NA 4
Current Portion Long-Term Debt 12 NA 4 NA 3
Current Portion Capital Leases NA NA 0 NA NA
Accrued Expenses 3 NA 3 NA 3
Income Taxes Payable 0 NA 0 NA 2
Other Current Liabilities 17 NA 17 NA 18
Total Current Liabilities 40 NA 31 NA 39
Mortgages NA NA 0 NA NA
Deferred Taxes/Income NA NA 0 NA NA
Convertible Debt NA NA 0 NA NA
Long-Term Debt 5 NA 14 NA 13
Non-Current Capital Leases NA NA 0 NA NA
Other Non-Current Liabilities NA 0 NA 0
Minority Interest (Liabilities) NA NA 0 NA NA
Total Liabilities 44 NA 45 NA 53
Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Preferred Stock NA NA 0 NA NA
Common Stock (Par) 0 NA 0 NA 0
Capital Surplus 353 NA 350 NA 347
Retained Earnings -295 NA -278 NA -263
Other Equity -1 NA -2 NA -1
Treasury Stock 0 NA 0 NA 0
Total Shareholder's Equity 57 NA 71 NA 83
Total Liabilities & Shareholder's Equity 101 NA 116 NA 135
Total Common Equity 100,056 0 71 0 100,082
Shares Outstanding 44.10 44.10 43.80 43.80 43.70
Book Value Per Share 2,268.83 0.00 1.61 0.00 2,290.20